Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
Date:1/31/2008

Thursday, February 7th, 11:00 a.m. EST

WALTHAM, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, February 7th, 2008 at 11:00 a.m. EST, to report third quarter fiscal year 2008 financial results and to provide a quarterly update of the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at http://www.repligen.com. If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (888) 713-4216 for domestic calls and (617) 213-4868 for international calls. Participants must provide the following passcode: 98169734. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at http://www.repligen.com.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Hologic Announces First Quarter Fiscal 2008 Operating Results
3. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
4. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Genelabs Technologies, Inc. Announces Resignation of President and CEO
9. CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board
10. BioHorizons Announces Agreement to Purchase Implant Logic Systems
11. AlphaVax Announces New CMV Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 21, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... team to lead the development and commercialization of its Cancer Information Data Trust ... and treatment of cancer. The CIDT addresses the need for curated and structured ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... and manufacturing solutions for original equipment manufacturers (OEMs) , today announced it has ... Technologies’ third consecutive year winning in its category of electronics manufacturing services (EMS) ...
(Date:2/21/2017)... , February 21, 2017 ... Technology for Adoption by Plastic Industry  ... STEER, creator ... functionalise materials in the fields of plastics, pharmaceuticals, food and ... with Merck, a leading science & technology company, on ...
(Date:2/20/2017)... , Feb. 20, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... President and CEO and Fabrice Orecchioni, the company,s COO, has been ... COO over the past four years, Fabrice has overseen the construction, ... and the management of the Mitsui JV.  Fabrice has ... the proposed China JV. ...
Breaking Biology Technology:
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):